Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Spyre Therapeutics, Inc. (SYRE)
Price$88.98Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886,000 | $2.3M | $18.7M | $0 | $0 | $3.9M | $5.2M | $4.6M | — | — |
| Research & development | $171.7M | $162.8M | $89.5M | $58.6M | $57.1M | $59.6M | $64.6M | $36.7M | $22.8M | $18.1M | $11.5M | $6.8M |
| Operating expenses | $209.6M | $208.6M | $243.2M | $87.1M | $84.4M | $81.5M | $80.3M | $49.4M | $32.9M | $26.5M | $17.4M | $8.9M |
| Operating income | −$209.6M | −$208.6M | −$242.3M | −$84.8M | −$65.6M | −$81.5M | −$80.3M | −$45.5M | −$27.7M | −$21.9M | −$11.3M | −$8.9M |
| Operating margin | — | — | −27,347.97% | −3,640.23% | −350.33% | — | — | −1,169.32% | −531.72% | −473.34% | — | — |
| EBITDA | −$209.6M | −$208.6M | −$241.6M | −$83.2M | −$64.1M | −$80.5M | −$79.9M | −$45.2M | −$27.4M | −$21.8M | −$11.2M | −$8.9M |
| EBITDA margin | — | — | −27,264.00% | −3,572.95% | −341.92% | — | — | −1,161.78% | −526.94% | −470.48% | — | — |
| Net income | −$155.2M | −$208.0M | −$338.8M | −$83.8M | −$65.8M | −$80.9M | −$78.3M | −$44.3M | −$27.2M | −$21.7M | −$11.3M | −$10.3M |
| Net profit margin | — | — | −38,238.15% | −3,598.75% | −351.14% | — | — | −1,140.64% | −523.27% | −468.84% | — | — |
| Basic EPSper basic share | -$1.98 | -$3.18 | $13.76 | -$24.86 | -$25.02 | -$38.00 | -$61.25 | -$53.25 | -$45.00 | -$55.50 | -$480.25 | — |
| Diluted EPSper diluted share | -$1.98 | -$3.18 | $13.76 | -$24.86 | -$25.02 | -$38.00 | -$61.25 | -$53.25 | -$45.00 | -$55.50 | -$480.25 | — |
Owners
Reported shareholders
14.79%of listed shares
FMR LLC13.03M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 14.79%13.03M shares |
BlackRock, Inc. | 7.39%6.51M shares |
PERCEPTIVE ADVISORS LLC | 4.90%4.32M shares |
RTW INVESTMENTS, LP | 4.83%4.25M shares |
Paradigm Biocapital Advisors LP | 4.36%3.84M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.92%3.45M shares |
STATE STREET CORP | 3.47%3.06M shares |
Venrock Adviser, LLC | 3.39%2.99M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 3.36%2.96M shares |
Driehaus Capital Management LLC | 3.18%2.8M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.91%2.56M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 2.65%2.33M shares |
Capital World Investors | 2.63%2.32M shares |
Jupiter Topco LLC | 2.51%2.21M shares |
TCG Crossover Management, LLC | 2.16%1.9M shares |
TANG CAPITAL MANAGEMENT LLC | 2.15%1.89M shares |
BANK OF AMERICA CORP /DE/ | 2.02%1.78M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.96%1.72M shares |
WELLINGTON MANAGEMENT GROUP LLP | 1.80%1.58M shares |
GOLDMAN SACHS GROUP INC | 1.68%1.48M shares |
Percentages use 88.06M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 | Burrows Scott LChief Financial Officer | SellCommon Stock | 10.0K | $87.14 | $871.4K | 98.0K |
| Jun 25, 2026Form 4 | Burrows Scott LChief Financial Officer | SellCommon Stock | 5.0K | $87.12 | $435.6K | 108.0K |
| Jun 23, 2026Form 4 | Fairmount Funds Management LLC +3Director | SellCommon Stock · indirect | 4.68M | $85.31 | $399.66M | 0 |
| Jun 22, 2026Form 4 · 10b5-1 | HENDERSON MICHAEL THOMASDirector | SellCommon Stock | 20.0K | $100.00 | $2.00M | 68.6K |
| Jun 3, 2026Form 4 · 10b5-1 | Sloan SheldonChief Medical Officer | SellCommon Stock | 8.3K | $75.00 | $625.0K | 0 |